相似文献
1
Spontaneous pyohaemothorax in a teenager with von Willebrand disease: a case report and review of literature.
BMJ Case Rep. 2021 Aug 17;14(8):e241613. doi: 10.1136/bcr-2021-241613.
2
Clinical Efficacy and Safety of Fanhdi, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study.
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221074348. doi: 10.1177/10760296221074348.
3
Von Willebrand's disease: case report and review of literature.
Pan Afr Med J. 2017 Jun 29;27:147. doi: 10.11604/pamj.2017.27.147.12248. eCollection 2017.
4
Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
Haemophilia. 2009 Jan;15(1):122-30. doi: 10.1111/j.1365-2516.2008.01901.x.
5
Clinical experience of prophylactic treatment in von Willebrand disease.
Thromb Res. 2006;118 Suppl 1:S9-11. doi: 10.1016/j.thromres.2006.01.021. Epub 2006 Apr 17.
6
Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
Haemophilia. 2002 Nov;8(6):761-7. doi: 10.1046/j.1365-2516.2002.00688.x.
7
Clinical diagnosis of von Willebrand disease.
Haemophilia. 2004 Oct;10 Suppl 4:169-76. doi: 10.1111/j.1365-2516.2004.00991.x.
8
Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature.
Haemophilia. 2022 Mar;28(2):286-291. doi: 10.1111/hae.14491. Epub 2022 Jan 10.
9
Severe Traumatic Brain Injury in a Patient with von Willebrand Disease Type 2A Successfully Treated with Factor VIII/von Willebrand Factor Concentrates: A Case Report.
Am J Case Rep. 2022 Aug 30;23:e936690. doi: 10.12659/AJCR.936690.
10
Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study.
Haemophilia. 2015 May;21(3):e185-e192. doi: 10.1111/hae.12670. Epub 2015 Apr 9.
本文引用的文献
1
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.
Blood Adv. 2021 Jan 12;5(1):301-325. doi: 10.1182/bloodadvances.2020003264.
2
Von Willebrand's Disease.
N Engl J Med. 2016 Nov 24;375(21):2067-2080. doi: 10.1056/NEJMra1601561.
3
Etiology and management of spontaneous haemothorax.
J Thorac Dis. 2015 Mar;7(3):520-6. doi: 10.3978/j.issn.2072-1439.2014.12.50.
4
Elevated factor VIII levels and risk of venous thrombosis.
Br J Haematol. 2012 Jun;157(6):653-63. doi: 10.1111/j.1365-2141.2012.09134.x. Epub 2012 Apr 25.
5
Haemothorax in children with congenital coagulopathy.
Haemophilia. 2010 Jul 1;16(4):688-91. doi: 10.1111/j.1365-2516.2010.02209.x. Epub 2010 Apr 7.
6
The prevalence of symptomatic von Willebrand disease in primary care practice.
J Thromb Haemost. 2010 Jan;8(1):213-6. doi: 10.1111/j.1538-7836.2009.03661.x. Epub 2009 Oct 23.
7
Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines.
Am J Hematol. 2009 Jun;84(6):366-70. doi: 10.1002/ajh.21405.
8
12-year experience of spontaneous hemopneumothorax.
Ann Thorac Cardiovasc Surg. 2008 Jun;14(3):149-53.
9
Coagulation disorders.
Pediatr Rev. 2003 Mar;24(3):83-91. doi: 10.1542/pir.24-3-83.
10
Spontaneous haemothorax: an uncommon presentation of Glanzmann thrombasthenia.
Acta Paediatr. 2002;91(10):1139-40. doi: 10.1080/080352502760311683.
Zotero 插件